Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.
Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—The FDA has granted 510(k) clearance for Diazyme Laboratories’ Lipoprotein(a) Molarity assay for use in the quantitative determination of Lp(a) levels in human serum and plasma, reported in molar units (nmol/L).
July 2026—OptraScan launched BactoSia, an AI-assisted tuberculosis treatment monitoring and follow-up solution designed to assist with sputum smear microscopy. BactoSia combines high-resolution brightfield whole-slide imaging with AI-based algorithms to detect and quantify acid-fast bacilli on Ziehl-Neelsen-stained sputum samples.
July 2026—Anchor Molecular has launched its MSI FFPE controls designed to support microsatellite instability assay development, validation, and routine quality control applications. Each product contains 10-µm FFPE tissue slices embedded with cellular DNA exhibiting either microsatellite stable (MSS) status or microsatellite instability-high (MSI-H) status.
July 2026—Seegene launched its new antimicrobial resistance testing product, the Allplex MDRO assay. The assay, which is CE marked under the EU in vitro diagnostic regulation, is designed to identify key multidrug-resistant pathogens and associated resistance genes in a single run and can support same-day reporting, depending on laboratory workflow.
July 2026—Sysmex America has introduced the XR-Series, a hematology solution designed to help laboratories deliver fast, reliable results while maintaining efficient workflows. The next-generation XR-Series builds on the capabilities of the XN-Series, adding higher throughput, enhanced analytics, and complementary solutions that aim to streamline daily laboratory operations.
July 2026—Roche introduced the Cobas MPX-E assay, a qualitative in vitro test for the detection and discrimination of HIV 1 and 2 and hepatitis C, B, and E viruses, in countries accepting the CE mark. By identifying these pathogens simultaneously, the assay aims to help laboratories streamline their operations while enhancing the safety of blood and blood products for patients.
July 2026—Tempus AI has launched the ArteraAI Prostate test (mHSPC) for clinical use. The test uses multimodal artificial intelligence to provide insights for personalized care for patients with metastatic hormone-sensitive prostate cancer.
July 2026—Streck has launched MDx-Chex for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis and MDx-Chex for MVP (multiplex vaginal panel) for research use only.
July 2026—QuidelOrtho has completed the acquisition of Lex Diagnostics for about $100 million in cash. The acquisition follows the FDA 510(k) clearance and CLIA waiver of the Lex Velo molecular diagnostics platform in February.
July 2026—CareDx has entered into a definitive agreement to acquire Naveris for $160 million up front plus up to $100 million in additional payments tied to revenue milestones. Naveris is a precision oncology diagnostics company with a Medicare-reimbursed, blood‑based monitoring test for cancers caused by viral infections.
